Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization time 51% Improvement Relative Risk Time to viral- 56% c19hcq.org Kim et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 97 patients in South Korea Shorter hospitalization (p=0.014) and faster viral clearance (p=0.0047) Kim et al., medRxiv, doi:10.1101/2020.05.13.20094193 Favors HCQ Favors control

Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea

Kim et al., medRxiv, doi:10.1101/2020.05.13.20094193 (Preprint)
Kim et al., Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First.., medRxiv, doi:10.1101/2020.05.13.20094193 (Preprint)
May 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiotic. Preprint withdrawn pending peer review.
hospitalization time, 51.0% lower, relative time 0.49, p = 0.01, treatment 22, control 40.
time to viral-, 56.0% lower, relative time 0.44, p = 0.005, treatment 22, control 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 18 May 2020, retrospective, South Korea, preprint, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.13.20094193; this version posted June 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea Min Seo Kim, MD, Soon-Woo Jang, MD, KMD, Yu-Kyung Park, MD, Bong-Ok Kim, MD, PhD, Tae-Ho Hwang, DSS, PhD, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD, Park Sung Kyu, MD, Hea-Woon Park, MD, PhD, Wonjong Yang, MD, Joonyoung Jang, MD, Min Ho An, MD The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit